> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Tightens Sotrovimab EUA
- URL: https://www.fdaweb.com/fda-tightens-sotrovimab-eua/
- Published: 2022-02-24T12:00:00.000Z
- Updated: 2026-09-14T17:34:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151233

FDA has tightened its emergency use authorization for GlaxoSmithKline/Vir Biotech’s sotrovimab to restrict its use in some cases. The monoclonal antibody is a treatment for mild-to-moderate Covid-19 in adults and children age 12 and older with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe Covid-19, including hospitalization or death.

The revised [authorization](https://www.fda.gov/media/149534/download?ref=fdaweb.com) says sotrovimab should not be used in geographic locations with circulation of variants that are not susceptible to it. The latest changes also cover dosage and administration, overall safety summary and clinical trial experience, and microbiology/resistance information.